letrozole has been researched along with Dyslipidemia in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 8.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 4.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olaniyi, KS | 1 |
| Areloegbe, SE | 1 |
| Areola, ED | 1 |
| Sabinari, IW | 1 |
| Fafure, AA | 1 |
| Agbana, RD | 1 |
| Atuma, CL | 1 |
| Shah, MZUH | 1 |
| Ajadi, IO | 1 |
| Olatunji, LA | 1 |
| Aliev, DA | 1 |
| Azizov, VA | 1 |
| Sadygova, TA | 1 |
| Zeĭnalov, RS | 1 |
| Musaev, IN | 1 |
1 trial available for letrozole and Dyslipidemia
| Article | Year |
|---|---|
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipide | 2009 |
1 other study available for letrozole and Dyslipidemia
| Article | Year |
|---|---|
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Topics: Animals; Dyslipidemias; Female; Humans; Inflammation; Letrozole; NLR Family, Pyrin Domain-Containing | 2023 |